Table 1.
Demographic and Clinical Characteristics by Group (N = 109)
| Overall (N = 109) | Booklet (N = 62) | Web (N = 47) | p | |
|---|---|---|---|---|
| Mean (SD) | ||||
| Demographic characteristicsa | ||||
| Ageb | 57.6 (9.1) | 56.0 (9.2) | 59.8 (8.6) | 0.035 |
| Years of education | 15.5 (2.4) | 15.4 (2.4) | 15.6 (2.5) | 0.753 |
| N (%) | ||||
| Race | 0.864 | |||
| Black or African American | 11 (10.1) | 7 (11.3) | 4 (8.5) | |
| White | 94 (86.2) | 53 (85.5) | 41 (87.2) | |
| Multiple and Other | 4 (3.7) | 2 (3.2) | ||
| Ethnicity | 0.190 | |||
| Hispanic or Latina | 4 (3.7) | 1 (1.6) | 3 (6.4) | |
| Not Hispanic or Latina | 105 (96.3) | 661 (98.4) | 44 (93.6) | |
| Partnered (married/living with partner) | N = 108 | N = 61 | 0.924 | |
| No | 35 (32.4) | 20 (32.8) | 15 (31.9) | |
| Yes | 73 (67.6) | 41 (67.2) | 32 (68.1) | |
| Residence | 0.148 | |||
| City | 70 (64.2) | 35 (56.5) | 35 (74.5) | |
| Country | 25 (22.9) | 17 (27.4) | 8 (17.0) | |
| Other | 14 (12.8) | 10 (16.1) | 4 (8.5) | |
| Employment | N = 108 | N = 61 | 0.844 | |
| Employed | 56 (51.9) | 33 (54.1) | 23 (48.9) | |
| Not employed | 44 (40.7) | 24 (39.3) | 20 (42.6) | |
| Other | 8 (7.4) | 4 (6.6) | 4 (8.5) | |
| Insurance | 0.347 | |||
| Government | 22 (20.2) | 10 (16.1) | 12 (25.5) | |
| Private | 59 (54.1) | 37 (59.7) | 22 (46.8) | |
| Multiple and other | 28 (25.7) | 15 (24.2) | 13 (27.7) | |
| Annual income | N = 108 | N = 61 | 0.983 | |
| Up to $30,000 | 19 (17.6) | 11 (18.0) | 8 (17.0) | |
| More than $30,000 | 69 (63.9) | 39 (63.9) | 30 (63.8) | |
| Do not care to respond | 20 (18.5) | 11 (18.0) | 9 (19.1) | |
| Clinical characteristics | ||||
| Chemotherapy | N = 106 | N = 61 | N = 45 | 0.664 |
| None | 16 (15.1) | 10 (16.4) | 6 (13.3) | |
| Some | 90 (84.9) | 51 (83.6) | 39 (86.7) | |
| Taxane Chemo | N = 81 | N = 43 | N = 38 | 0.249 |
| No | 13 (16.0) | 5 (11.6) | 8 (21.1) | |
| Yes | 68 (84.0) | 38 (88.4) | 30 (78.9) | |
| Radiation therapy | 0.735 | |||
| None | 32 (29.4) | 19 (30.6) | 13 (27.7) | |
| Some | 77 (70.6) | 43 (69.4) | 34 (72.3) | |
| Complete treatment received | N = 108 | N = 61 | 0.580 | |
| Surgery alone | 7 (6.5) | 3 (4.9) | 4 (8.5) | |
| Surgery and radiation | 8 (7.4) | 6 (9.8) | 2 (4.3) | |
| Surgery and chemotherapy | 23 (21.3) | 14 (23.0) | 9 (19.1) | |
| Surgery, radiation, and chemotherapy | 70 (64.8) | 38 (62.3) | 32 (68.1) | |
| Surgery type | 0.350 | |||
| Breast conserving | 30 (27.5) | 18 (29.0) | 12 (25.5) | |
| Breast sacrificing | 57 (52.3) | 29 (46.8) | 28 (59.6) | |
| Multiple and other | 22 (20.2) | 15 (24.2) | 7 (14.9) | |
| Reconstruction | 0.952 | |||
| None | 56 (51.4) | 32 (51.6) | 24 (51.1) | |
| Immediate | 22 (20.2) | 13 (21.0) | 9 (19.1) | |
| Delayed | 31 (28.4) | 17 (27.4) | 14 (29.8) | |
| Hormone inhibitor use | N = 100 | N = 55 | N = 45 | 0.809 |
| No | 52 (52.0) | 28 (50.9) | 24 (53.3) | |
| Yes | 48 (48.0) | 27 (49.1) | 21 (46.7) | |
| Regular medications | N = 108 | N = 61 | 0.957 | |
| No | 14 (13.0) | 8 (13.1) | 6 (12.8) | |
| Yes | 94 (87.0) | 53 (86.9) | 41 (87.2) | |
| Menstrual status | N = 108 | N = 61 | 0.115 | |
| Premenopausal | 10 (9.3) | 8 (13.1) | 2 (4.3) | |
| Postmenopausal | 98 (90.7) | 53 (86.9) | 45 (95.7) | |
| Current treatment for lymphedema | N = 107 | N = 61 | N = 46 | |
| None | 10 (9.3) | 7 (11.5) | 3 (6.5) | 0.383 |
| CDT | 31 (29.0) | 17 (27.9) | 14 (30.4) | 0.772 |
| Pump | 1 (0.9) | 1 (1.6) | 0 (0.0) | 0.383 |
| Compression sleeve | 41 (38.3) | 20 (32.8) | 21 (45.7) | 0.175 |
| Arm elevation | 14 (13.1) | 5 (8.2) | 9 (19.6) | 0.084 |
| Medication only | 1 (0.9) | 0 (0.0) | 1 (2.2) | 0.247 |
| CDT and pump | 5 (4.7) | 4 (6.6) | 1 (2.2) | 0.288 |
| Pump and compression sleeve | 19 (17.8) | 12 (19.7) | 7 (15.2) | 0.551 |
| Arm elevation and medication | 4 (3.7) | 3 (4.9) | 1 (2.2) | 0.459 |
| Night bandaging | 26 (24.3) | 13 (21.3) | 13 (28.3) | 0.407 |
| Arm exercises, skin care, compression sleeve, and bandaging | 52 (48.6) | 26 (42.6) | 26 (56.5) | 0.154 |
| Other | 25 (23.4) | 13 (21.3) | 12 (26.1) | 0.563 |
| Median [IQR], (minimum, maximum) N | ||||
| Months since first surgery | 79.1 [34–139], (0, 535) | 84.0 [35–172], (0, 500) | 77.2 [33–113], (1, 535) | 0.485 |
| Months since last surgery | 75.0 [24–129], (0, 535) | 80.4 [24–146], (0, 385) | 73.9 [22–112], (0, 535) | 0.664 |
| Months since last treatment | 68.2 [19–122], (0, 529) | 60.7 [14–122], (0, 499) | 68.7 [23–118], (0, 529) | 0.997 |
| No. of skin conditions at baseline, affected arm | 2.0 [1–4], (0, 9) | 2.0 [1–5], (0, 8) | 2.0 [1–3], (0, 9) | 0.098 |
| No. of skin conditions at baseline, unaffected arm | 1.0 [0–1], (0, 9) | 1.0 [0–2], (0, 8) | 1.0 [0–1], (0, 9) | 0.373 |
a
All participants were female.
b
N = 105, Booklet N = 60, Web N = 45.
CDT, complex decongestive therapy; IQR, interquartile range; SD, standard deviation.